专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130065276A1 COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS 有权
公开(公告)号：US20130065276A1
公开(公告)日：2013-03-14
申请号：US13227398
申请日：2011-09-07
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC分类号： C12P21/00 , C12N5/073 , C12N5/07 , C12N15/13 , C12N15/85
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

2. 发明申请

US20110281302A1 COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS 有权
标题翻译：用FGFR融合蛋白治疗疾病的组合物和方法
公开(公告)号：US20110281302A1
公开(公告)日：2011-11-17
申请号：US13157712
申请日：2011-06-10
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC分类号： C12P21/04 , C12N5/10 , C07H21/04 , C07K14/00 , C07K16/46
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译：本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。这些融合蛋白体外和体内抑制癌细胞的生长和活力。这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

3. 发明申请

US20060035373A1 Stem cell libraries 审中-公开
标题翻译：干细胞库
公开(公告)号：US20060035373A1
公开(公告)日：2006-02-16
申请号：US11003840
申请日：2004-12-06
申请人： Hongbing Zhang , Lewis Williams , Keting Chu , Fred Cohen
发明人： Hongbing Zhang , Lewis Williams , Keting Chu , Fred Cohen
IPC分类号： C12N5/08 , C12N15/87 , C40B40/02
CPC分类号： C12N5/0606
摘要： A stem cell library is created by genetically modifying stem cells with nucleic acids encoding polypeptides which can promote stem cell differentiation into specific cell types. Alternatively, the stem cell library is exposed to an externally added factor that promotes stem cell differentiation into a desired cell line, e.g., neuronal or muscle. The library is used to determine the effect of the encoded protein on the differentiation process. The library is also used to produce nucleic acids for insertion into embryonic stem cells to produce transfected embryonic stem cells. The nucleic acids are inserted into a locus that permits widespread expression of the encoded polypeptide in animals produced from blastocysts that incorporate the transfected cells. Non-human chimeric animals produced by combining blastocysts derived from animal models of human disease and embryonic stem cells transfected with molecules from the library provide an in vivo system for therapeutic design.
摘要翻译：通过用能够促进干细胞分化成特定细胞类型的多肽的核酸对遗传修饰干细胞产生干细胞文库。或者，干细胞文库暴露于促进干细胞分化成所需细胞系（例如神经元或肌肉）的外部添加因子。该文库用于确定编码的蛋白质对分化过程的影响。该文库还用于生产用于插入胚胎干细胞以产生转染的胚胎干细胞的核酸。将核酸插入到允许编码的多肽在掺入转染细胞的囊胚产生的动物中广泛表达的基因座。通过将源自人类疾病的动物模型的胚泡和来自文库的分子转染的胚胎干细胞组合产生的非人类嵌合动物提供用于治疗设计的体内系统。

4. 发明申请

US20100158911A1 Compositions and Methods of Treating Disease with FGFR Fusion Proteins 有权
标题翻译：用FGFR融合蛋白治疗疾病的组合物和方法
公开(公告)号：US20100158911A1
公开(公告)日：2010-06-24
申请号：US12652720
申请日：2010-01-05
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC分类号： A61K39/395 , C07K19/00 , C07K14/00 , C07H21/04 , A61K38/16 , A61P35/00 , A61P35/04 , C12N5/10 , C12P21/06 , C12N15/63 , G01N33/53
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译：本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。这些融合蛋白体外和体内抑制癌细胞的生长和活力。这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

5. 发明申请

US20090300230A1 Systems and Methods for Improved Hardware Device Connectivity 有权
标题翻译：改进硬件设备连接的系统和方法
公开(公告)号：US20090300230A1
公开(公告)日：2009-12-03
申请号：US11992862
申请日：2005-09-29
申请人： Brett Wang , Minqiang Wu , Winters Zhang , Hongbing Zhang
发明人： Brett Wang , Minqiang Wu , Winters Zhang , Hongbing Zhang
IPC分类号： G06F13/10
CPC分类号： G06F13/4291
摘要： Systems and methods are described herein to provide for improved hardware device connectivity. Other embodiments include apparatus and system for receiving messages from an operating system and sending messages to one or more hardware devices. Further embodiments include methods for receiving messages from an operating system regarding operations on a hardware device and responding to those messages. Other embodiments include methods for receiving interrupt messages and mapping those interrupt messages to hardware devices. Other embodiments are described and claimed.
摘要翻译：本文描述了系统和方法以提供改进的硬件设备连接性。其他实施例包括用于从操作系统接收消息并向一个或多个硬件设备发送消息的装置和系统。另外的实施例包括用于从操作系统接收关于硬件设备上的操作并响应于那些消息的消息的方法。其他实施例包括用于接收中断消息并将这些中断消息映射到硬件设备的方法。描述和要求保护其他实施例。

6. 发明授权

US07537759B2 Modulating angiogenesis 有权
公开(公告)号：US07537759B2
公开(公告)日：2009-05-26
申请号：US11085949
申请日：2005-03-21
申请人： Duojia Pan , Gerald M. Rubin , Hongbing Zhang
发明人： Duojia Pan , Gerald M. Rubin , Hongbing Zhang
IPC分类号： A01N37/18 , A61K38/00
CPC分类号： A61K31/405 , A61K31/198 , A61K31/381 , A61K38/4886 , A61K2039/505 , C07K16/18 , C12Q1/37 , G01N33/573 , G01N2333/96486 , G01N2500/04 , G01N2500/10
摘要： The invention provides methods and compositions relating to Kuz involvement in angiogenesis. In various embodiments, the invention provides methods for modulating angiogenesis by specifically modulating the activity of Kuz in a vertebrate animal predetermined to have a pathogenic angiogenesis; methods for modulating angiogenesis by specifically modulating the activity of Kuz in a vertebrate animal and subsequently detecting a resultant angiogenic modulation in the animal; methods for specifically detecting Kuz activity in a vertebrate animal predetermined to have a pathogenic angiogenesis; methods for specifically detecting a pathogenic angiogenesis in a vertebrate animal having a predetermined Kuz activity; and methods for identifying a modulator of angiogenesis by (a) contacting an angiogenic assay system comprising a predetermined amount of Kuz with a candidate agent, under conditions whereby but for the presence of the agent, the system provides a reference angiogenesis; and (b) detecting an agent-biased angiogenesis of the system.

7. 发明申请

US20080112937A1 Method of Producing Autologous Embryonic Stem Cells 审中-公开
标题翻译：生产自体胚胎干细胞的方法
公开(公告)号：US20080112937A1
公开(公告)日：2008-05-15
申请号：US11632860
申请日：2005-07-19
申请人： Lewis T Williams , Hongbing Zhang , Srinivas Kothakota , Kristen Pierce , Pierre Alvaro Beaurang , Keting Chu
发明人： Lewis T Williams , Hongbing Zhang , Srinivas Kothakota , Kristen Pierce , Pierre Alvaro Beaurang , Keting Chu
IPC分类号： A61K48/00 , C12N5/08 , C12N15/09
CPC分类号： C12N5/0606 , A01K2217/05 , C12N15/873 , C12N2506/00
摘要： Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric embryo, allowing the chimeric embryo to develop further wherein the somatic cell will reprogram, and then selecting an autologous embryonic stem cell that has developed from the somatic cell. The methods and composition of producing pluripotent embryonic stem cells from a donor's own somatic cells invite the possibility of a number of therapeutic applications, including organ transplant and treatment of autoimmune diseases, cancer, and degenerative disorders such as diabetes, Alzheimer's, and Parkinson's.
摘要翻译：本发明的方面涉及重编程体细胞以产生自体胚胎干细胞的组合物和方法。这些方法涉及提供供体受试者的体细胞，将体细胞引入受体的胚胎以产生嵌合胚胎，允许嵌合胚胎进一步发育，其中体细胞将重新编程，然后选择自体胚胎干从体细胞发育而来的细胞。从供体自身体细胞细胞产生多能胚胎干细胞的方法和组成可引起许多治疗应用的可能性，包括器官移植和治疗自身免疫性疾病，癌症和退行性疾病如糖尿病，阿尔茨海默病和帕金森病。

8. 发明申请

US20120183477A1 Therapeutic Antibody Target Validation and Screening In Vivo 审中-公开
标题翻译：治疗性抗体目标验证和筛选体内
公开(公告)号：US20120183477A1
公开(公告)日：2012-07-19
申请号：US13378318
申请日：2010-06-25
申请人： Lewis T. Williams , Justin Wong , Hongbing Zhang
发明人： Lewis T. Williams , Justin Wong , Hongbing Zhang
IPC分类号： A61K49/00
CPC分类号： A61K49/0008 , A61K2039/505 , C07K16/00 , C07K16/32 , C12N15/85 , C12N2800/30 , C12N2800/80 , C12N2840/20 , G01N33/5088 , G01N2500/10 , G01N2800/52
摘要： An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided.
摘要翻译：提供了验证候选治疗靶分子的体内方法。还提供了选择特定靶分子的治疗性抗体的体内方法。

9. 发明授权

US07982014B2 FGFR3-IIIc fusion proteins 有权
标题翻译： FGFR3-IIIc融合蛋白
公开(公告)号：US07982014B2
公开(公告)日：2011-07-19
申请号：US12652720
申请日：2010-01-05
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC分类号： A61K38/00 , A61K38/18 , A61K39/00
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译：本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。这些融合蛋白体外和体内抑制癌细胞的生长和活力。这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

10. 发明授权

US07115793B2 Isolation and identification of transcription control elements associated with mouse eosinophil peroxidase expression 有权
公开(公告)号：US07115793B2
公开(公告)日：2006-10-03
申请号：US10990112
申请日：2004-11-16
申请人： Hongbing Zhang , Pamela Contag , Anthony Purchio , Amy Holt
发明人： Hongbing Zhang , Pamela Contag , Anthony Purchio , Amy Holt
IPC分类号： G01N33/00 , A01K67/027 , C07H21/04
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0381 , A01K2267/0393 , C12N2830/008
摘要： The present invention relates to novel transcription control elements derived from a mouse eosinophil peroxidase gene. Such transcription control elements may comprise isolated polynucleotides, expression cassettes, vectors, recombinant cells, and transgenic animals, as described herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式